Nebraska Center for Integrated Biomolecular Communication (CIBC)

项目概要/摘要 生物分子通讯途径的调节对于维持生理功能至关重要。解开 这些途径和填补关键知识空白将为理解、诊断、 并治疗人类疾病。在第一阶段，内布拉斯加州综合生物分子通讯中心 (CIBC) 支持 15 名早期研究人员 (ESI)，帮助大学招募了四名新教员 内布拉斯加州林肯分校（UNL），并建立了两个研究核心。 CIBC 的 ESI 获得了 1,670 万美元的外部融资 研究基金并撰写了 82 篇同行评审出版物。以第一阶段为基础，CIBC 第一阶段的目标 二是继续培养足够数量的生物医学研究人员并支持研究基础设施 UNL 的生物分子通讯途径领域将使 CIBC 成功过渡到长期 第三阶段的长期可持续性。CIBC 将继续发展多学科团队来审视复杂的情况 疾病途径，特别是通过将开发新分子探针和分析的研究人员联系起来 揭示人类疾病分子机制的技术。 CIBC 第二阶段的具体目标 目的是： 1) 通过支持研究工作和职业来加强内布拉斯加州大学的生物医学研究基础设施 生物医学研究者的发展，他们的研究广泛集中于理解生物医学的调控 生物医学相关的沟通途径； 2）通过维持和扩展来增强研究能力 系统生物学核心（SBC），以促进基本生物分析数据以及数据和生命的获取 Science Core (DLSC) 提供关键的生物信息学支持以及数据管理、存储和共享 中心成员； 3）推进具有广泛学科代表性的跨学科研究合作 从不同的角度对复杂疾病进行高影响力的研究。初步二期工程 领导者将开展因基本关注生物分子不同方面而相互关联的项目 疾病相关通讯途径的基础。这些项目标志着 CIBC 的跨学科 性质，旨在：1）开发新型化学探针和靶向质谱方法 研究可卡因和安非他明调节的转录肽和受体，2) 了解 7SK RNP 调节转录及其对人类疾病的影响，3) 进行近实时检测 通过开发基于电化学肽的通用生物传感来检测耐甲氧西林金黄色葡萄球菌 平台，以及 4) 开发一种新型的基于非天然氨基酸的染色质分离方法 (UChIMe) 提高了准确性和灵敏度。 CIBC 将进一步扩展 SBC 和 DLSC，以使内布拉斯加州的生物医学 研究人员追求高影响力的生物医学研究。 CIBC 的创新在于整合研究活动 化学家、生物化学家、工程师和生物信息学家了解细胞如何沟通和整合 与疾病发生和进展相关的代谢和调节途径。

PROJECT SUMMARY/ABSTRACT Regulation of biomolecular communication pathways is critical to maintaining physiological function. Unraveling these pathways and filling in critical knowledge gaps will provide novel opportunities to understand, diagnose, and treat human diseases. During Phase 1, the Nebraska Center for Integrated Biomolecular Communication (CIBC) supported 15 early stage investigators (ESIs), helped recruit four new faculty members to the University of Nebraska-Lincoln (UNL), and established two research cores. CIBC’s ESIs secured $16.7 million in external research funds and authored 82 peer-reviewed publications. Building on Phase 1, the goal of the CIBC in Phase 2 is to continue building a critical mass of biomedical investigators and supporting research infrastructure in the area of biomolecular communication pathways at UNL that will position CIBC for a successful transition to long- term sustainability in Phase 3. CIBC will continue to develop multidisciplinary teams to interrogate complex disease pathways, especially by connecting researchers developing new molecular probes and analytical techniques with those unravelling molecular mechanisms of human diseases. CIBC’s Phase 2 specific aims are to: 1) strengthen UNL’s biomedical research infrastructure by supporting the research efforts and career development of biomedical investigators whose research is broadly focused on understanding the regulation of biomedically relevant communication pathways; 2) enhance research capabilities by maintaining and expanding the Systems Biology Core (SBC) to facilitate acquisition of essential bioanalytical data and the Data and Life Sciences Core (DLSC) to provide critical bioinformatics support and data management, storage, and sharing to Center members; and 3) advance interdisciplinary research collaborations with broad disciplinary representation to pursue high-impact research into complex disease from diverse perspectives. The initial Phase 2 Project Leaders will pursue projects interrelated by their fundamental focus on different aspects of the biomolecular basis of disease-associated communication pathways. These projects, which signify CIBC’s interdisciplinary nature, are directed toward: 1) developing novel chemical probes and targeted mass spectrometry approaches to study the cocaine and amphetamine-regulated transcript peptide and receptor(s), 2) understanding how the 7SK RNP regulates transcription and its implications in human diseases, 3) conducting near real-time detection of methicillin-resistant S. aureus by developing a generalizable electrochemical peptide-based biosensing platform, and 4) developing a novel Unnatural Amino Acid-based Chromatin Isolation Method (UChIMe) with improved accuracy and sensitivity. CIBC will further expand SBC and DLSC to enable Nebraska’s biomedical researchers to pursue high-impact biomedical research. CIBC’s innovation is in integrating the research activities of chemists, biochemists, engineers, and bioinformaticians to understand how cells communicate and integrate metabolic and regulatory pathways relevant to disease development and progression.